Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
-
Published:2024-01
Issue:
Volume:
Page:
-
ISSN:1071-9164
-
Container-title:Journal of Cardiac Failure
-
language:en
-
Short-container-title:Journal of Cardiac Failure
Author:
Felker G. MichaelORCID, Solomon Scott D., Metra Marco, Mcmurray John J.V., Diaz Rafael, Claggett Brian, Lanfear David E., Vandekerckhove Hans, Biering-Sørensen Tor, Lopes Renato D., Arias-Mendoza Alexandra, Momomura Shin-Ichi, Corbalan Ramon, Ramires Felix J.A., Zannad Faiez, Heitner Stephen B., Divanji Punag H., Kupfer Stuart, Malik Fady I., Teerlink John R.
Reference21 articles.
1. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials;Teerlink;Eur J Heart Fail,2020 2. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial;Teerlink;Lancet,2016 3. Acute Treatment With Omecamtiv Mecarbil To Increase Contractility in Acute Heart Failure: the ATOMIC-AHF Study;Teerlink;J Am Coll Cardiol,2016 4. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure;Latini;Circulation,2007 5. Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications;Kociol;J Am Coll Cardiol,2010
|
|